Therapeutic monoclonal antibodies

Research and Markets (2005d), Monoclonal antibody therapeutics current market dynamics future outlook. Available at http //www.researchandmarkets.com/ reportinfo.asp report id=75046 (accessed May 2005). [Pg.408]

An example of results from a tissue cross-reactivity study comparing binding of a monoclonal antibody therapeutic to human, cynomolgus monkey, and mouse tissues is shown in Table 9.2. A cell line that did not express the target was used as negative control tissue the same cell line transfected with the... [Pg.192]

Increasing the activity of monoclonal antibody therapeutics by continuous chromatography (MCSGP). Biotcchnol. Bioeng., 107, 652-662. [Pg.318]

Miiller-Spath, T, Kriittli, M., Aumann, L., Strohlein, G., and Morbidelli, M. (2010a) Increasing the activity of monoclonal antibody therapeutics by continuous chromatography (MCSGP). Biotechnol. Bioeng., 107, 652-662. [Pg.515]

Buss NA, Henderson SJ, McFarlane M, Shenton JM, de Haan L. Monoclonal antibody therapeutics history and future. Current Opinion in Pharmacology. 2012 12(5) 615—22. [Pg.37]

Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9 767-774... [Pg.73]

Nissim, A. and Chernajovsky, Y. (2008) Historical development of monoclonal antibody therapeutics. Handh. Exp. Pharmacol, 181, 3-18. [Pg.152]

Miller RA, Oseroff AR, Stratte FT, Levy R. Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 1983 62 988-995. [Pg.37]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...